The specter of generic competition has repeatedly loomed around copyright’s blockbuster drug, PDE5 Inhibitor, sparking questions about the prospects of connected drug ventures. While initial periods saw substantial profits, the patent lapse has allowed the way for discounted alternatives, possibly lowering earnings and presenting a real hazard fo